Written and maintained by CASRAI Editorial Board
Last updated
The Epworth Sleepiness Scale (ESS) is an 8-item self-administered patient-reported outcome measure (PROM) developed by Dr. Murray W. Johns in 1990 at Epworth Hospital in Melbourne, Australia, and published in the journal Sleep in 1991 to quantify a patient’s general level of daytime sleepiness. Whereas objective sleep medicine diagnostics—such as in-laboratory polysomnography (PSG), the Multiple Sleep Latency Test (MSLT), Maintenance of Wakefulness Test (MWT), and wrist actigraphy—measure physiological sleep architecture and latency, the Epworth Sleepiness Scale captures the patient’s subjective sleep propensity (behavioral likelihood of dozing off) across eight everyday sedentary situations.
In sleep medicine clinics and regulatory ePRO clinical trials, the Epworth Sleepiness Scale operates alongside two complementary validated sleep questionnaires: the 7-item Insomnia Severity Index (ISI) and the 19-item Pittsburgh Sleep Quality Index (PSQI).
How Is the 8-Item Johns Epworth Sleepiness Scale (ESS) Scored from 0 to 24 and What Are Its Severity Cutoffs?
A critical instructional distinction in Epworth Sleepiness Scale scoring is that the instrument asks the respondent how likely they are to doze off or fall asleep in contrast to simply feeling tired or fatigued during “recent times.” If a patient has not recently performed one of the eight activities (for example, riding as a passenger in a car for an hour), they are instructed to estimate how that situation would have affected them.
The 8 Situations and 0–3 Item Rating Scale
Each of the 8 situations is scored on a 4-point ordinal scale:
- 0 = Would never doze
- 1 = Slight chance of dozing
- 2 = Moderate chance of dozing
- 3 = High chance of dozing
The 8 standardized situations are:
- Sitting and reading
- Watching TV
- Sitting, inactive in a public place (e.g., a theater or a meeting)
- As a passenger in a car for an hour without a break
- Lying down to rest in the afternoon when circumstances permit
- Sitting and talking to someone
- Sitting quietly after a lunch without alcohol
- In a car, while stopped for a few minutes in traffic
ESS Total Score Range (0–24) and Official Johns Severity Cutoffs
Summing the 8 items yields a total score from 0 to 24. Under Dr. Murray Johns’s standardized interpretation bands, a score of 10 or lower represents normal daytime alertness, while a score of 11 or higher defines Excessive Daytime Sleepiness (EDS):
| Epworth Sleepiness Scale Score (0–24) | Clinical Interpretation Tier | Diagnostic & Clinical Trial Context |
|---|---|---|
| 0 to 5 | Lower Normal Daytime Sleepiness | Typical of healthy control populations without sleep-disordered breathing or sleep deprivation (mean healthy adult ESS ≈ 4.6 ± 2.8). |
| 6 to 10 | Higher Normal Daytime Sleepiness | Within upper normal physiological bounds. |
| 11 to 12 | Mild Excessive Daytime Sleepiness (EDS) | Exceeds the >10 pathological threshold; warrants evaluation for obstructive sleep apnea (OSA), insufficient sleep syndrome, or sedating medications. |
| 13 to 15 | Moderate Excessive Daytime Sleepiness (EDS) | Commonly observed in moderate-to-severe OSA; frequently used as an inclusion threshold (e.g., ESS ≥ 11 or ≥ 12) in wake-promoting pharmacotherapy trials. |
| 16 to 24 | Severe Excessive Daytime Sleepiness (EDS) | Indicates high propensity to doze even during active or socially engaging situations (items 6 and 8); characteristic of narcolepsy type 1/2, idiopathic hypersomnia, or severe untreated OSA. |
Pediatric adaptation: For children and adolescents aged 7 to 18 years, the validated ESS-CHAD (Epworth Sleepiness Scale for Children and Adolescents) replaces adult references (such as “after a lunch without alcohol” and driving/traffic context) with age-appropriate classroom and school situations while preserving the 0–24 scoring structure.
How Does the Epworth Sleepiness Scale Compare with the 7-Item Insomnia Severity Index (ISI) and 19-Item Pittsburgh Sleep Quality Index (PSQI)?
Because hypersomnolence (excessive propensity to fall asleep), insomnia (hyperarousal and inability to initiate or maintain sleep), and global sleep quality are distinct clinical constructs, sleep medicine researchers select among the ESS, ISI, and PSQI based on the target disorder:
| Dimension | Epworth Sleepiness Scale (ESS) | Insomnia Severity Index (ISI) | Pittsburgh Sleep Quality Index (PSQI) |
|---|---|---|---|
| Developer & Year | Murray W. Johns (1991, Sleep) | Charles M. Morin (1993; Bastien et al., 2001) | Daniel J. Buysse et al. (1989, Psychiatry Res) |
| Primary Clinical Construct | Daytime sleep propensity (excessive daytime sleepiness / hypersomnolence) | Nighttime insomnia severity and daytime distress/impairment | Global sleep quality and disturbances across 7 domains |
| Scored Item Count & Scale | 8 items (0–3 each) Total range: 0 to 24 |
7 items (0–4 each) Total range: 0 to 28 |
19 self-rated items combined into 7 component scores (0–3 each) Global range: 0 to 21 |
| Recall Period | “In recent times” (usual way of life) | Past 2 weeks | Past 1 month |
| Standard Clinical Cutoffs | 0–10: Normal 11–12: Mild EDS 13–15: Moderate EDS 16–24: Severe EDS |
0–7: No clinically significant insomnia 8–14: Subthreshold insomnia 15–21: Moderate clinical insomnia 22–28: Severe clinical insomnia |
Global Score ≤ 5: Good sleep quality Global Score > 5 (≥ 6): Poor sleep quality (89.6% sensitivity, 86.5% specificity) |
What Is the Minimal Clinically Important Difference (MCID) of the ESS and ISI in Sleep Medicine Clinical Trials?
In FDA and EMA clinical trials of continuous positive airway pressure (CPAP), hypoglossal nerve stimulation, wake-promoting agents (such as modafinil, armodafinil, solriamfetol, and pitolisant), dual orexin receptor antagonists (DORAs), and cognitive behavioral therapy for insomnia (CBT-I), responder analyses rely on validated MCID thresholds:
- Epworth Sleepiness Scale (ESS) MCID: In obstructive sleep apnea trials (Patel et al., 2018, Thorax; Crook et al., 2019, Eur Respir J), the Minimal Clinically Important Difference for the ESS is a reduction of 2 to 3 points (−2.0 to −3.0 points).
- Insomnia Severity Index (ISI) MCID and Responder Cutoffs: In longitudinal insomnia trials (Yang et al., 2009; Morin et al., 2011, Sleep), a 6-point reduction on the 0–28 ISI represents a clinically meaningful improvement (MCID), a reduction of ≥ 8 points (>7 points) identifies a marked treatment responder, and achieving an absolute post-treatment score of ISI < 8 (0–7) defines clinical remission.
- Pittsburgh Sleep Quality Index (PSQI) MCID: Across sleep intervention studies, a reduction of ≥ 3 points on the 0–21 Global PSQI score represents the standard MCID.
In digital health and decentralized sleep trials, all three instruments are encoded as structured HL7 FHIR Questionnaires and mapped to CDISC SDTM QS (Questionnaires) domains (QSCAT = "ESS", "ISI", or "PSQI") with automated scoring scripts that eliminate manual arithmetic errors across the PSQI’s 7 nonlinear component formulas.
Frequently Asked Questions
How is the 8-item Johns Epworth Sleepiness Scale (ESS) scored from 0 to 24 and what are its severity cutoffs?
The Epworth Sleepiness Scale (ESS) rates a person’s chance of dozing off in 8 daily situations on a 0 to 3 scale (0 = would never doze, 1 = slight chance, 2 = moderate chance, 3 = high chance), summing to a total score from 0 to 24. Scores of 0–10 indicate normal daytime alertness (0–5 lower normal, 6–10 higher normal), while scores above 10 indicate Excessive Daytime Sleepiness (EDS): 11–12 is mild EDS, 13–15 is moderate EDS, and 16–24 is severe EDS.
How does the Epworth Sleepiness Scale compare with the 7-item Insomnia Severity Index (ISI) and 19-item Pittsburgh Sleep Quality Index (PSQI)?
The 8-item ESS (0–24) measures daytime sleep propensity and hypersomnolence (used in obstructive sleep apnea and narcolepsy), the 7-item ISI (0–28, past 2 weeks; clinical insomnia cutoff ≥ 15) measures nighttime insomnia severity and daytime distress, and the 19-item PSQI (0–21 across 7 components, past 1 month; poor sleep quality cutoff > 5) measures overall subjective sleep quality and disturbances.
What is the Minimal Clinically Important Difference (MCID) of the ESS and ISI in sleep medicine clinical trials?
In sleep medicine clinical trials, the Minimal Clinically Important Difference (MCID) for the Epworth Sleepiness Scale (ESS) is a reduction of 2 to 3 points (−2 to −3 points). For the Insomnia Severity Index (ISI), a reduction of 6 points represents the MCID for clinically meaningful improvement, a reduction of ≥ 8 points defines a moderate-to-marked treatment response, and a post-treatment score < 8 indicates insomnia remission.
